(Q33974537)

30 July 2017

1 reference

title

Cytokines in rheumatoid arthritis: trials and tribulations (English)

1 reference

30 July 2017

1 reference

Carteron NL

1

1 reference

30 July 2017

publication date

1 August 2000

1 reference

Trends in Molecular Medicine

30 July 2017

published in

1 reference

30 July 2017

volume

6

1 reference

30 July 2017

issue

8

1 reference

30 July 2017

page(s)

315-323

1 reference

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two metaanalyses

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

Nonsteroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901757-3

7 January 2021

10.1016/S1357-4310(00)01757-3

Identifiers

DOI

1 reference

30 July 2017

1 reference